Chiral resolution, also known as enantiomeric resolution, is a stereochemical technique that separates racemic substances into their enantiomers. It is a critical tool in the manufacture of optically active molecules, including medicines. Optical resolution is another phrase for the same thing. The downside of using chiral resolution to generate enantiomerically pure molecules is that at least half of the beginning racemic mixture must be discarded. One method of eliminating this waste is asymmetric synthesis of one of the enantiomers. The most typical approach for chiral resolution includes reacting the racemic mixture with chiral derivatizing agents, also known as chiral resolving agents, to produce a pair of diastereomeric derivatives. The derivatives are then separated by conventional crystallisation and converted back to the enantiomers when the resolving agent is removed. The method can be time-consuming and is dependent on the diastereomers' differential solubilities, which are difficult to anticipate. The less soluble diastereomer is frequently targeted, while the other is discarded or racemized for reuse. It is typical practise to test several resolving agents. A typical derivatization reaction includes the production of a salt between an amine and a carboxylic acid. The pure enantiomer is then obtained by simple deprotonation. Tartaric acid and the amine brucine are examples of chiral derivatizing agents. Louis Pasteur (again) established the technique in 1853 by resolving racemic tartaric acid with optically active (+)-cinchotoxine.
Title : Application of vanadium and tantalum single-site zeolite catalysts in catalysis
Stanislaw Dzwigaj, Sorbonne University, France
Title : 30,000 nano implants in humans with no infections, no loosening, and no failures
Thomas J Webster, Interstellar Therapeutics, United States
Title : Solar heterogeneous photocatalysis and photochemistry for urban wastewater regeneration and reuse
Isabel Oller Alberola, Plataforma Solar de Almería, Spain
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through biodesign-inspired & biotech-driven translational applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, R&D Director of the National Center for Human Photosynthesis, Mexico
Title : Human impact on natural environment and its implications
Dai Yeun Jeong, Asia Climate Change Education Center, Korea, Republic of
Title : Effect of bed material on syngas quality: Comparison of biomass gasification with different bed materials
Enrico Paris, CREA-IT & DIAEE, Italy
Title : Valorizing lignocellulose to ethylene glycol: Catalysis, catalyst deactivation and conceptual process design
Jean Paul Lange, University of Twente, Netherlands
Title : Design of nanocomposite materials for active components of structured catalysts for biofuels transformation into syngas, catalytic layers of membrane reactors with oxygen/hydrogen separation and anodes of solid oxide fuels cells operating in the internal reforming mode
Vladislav Sadykov, Boreskov Institute of Catalysis, Russian Federation
Title : Cleaner syngas from biomass gasification: Is K-Feldspar the key?
Beatrice Vincenti, Sapienza University of Rome, Italy
Title : Sustainable catalyst development: metal modified lignin-plastic composites for hydrogen production
Tahreem Saleem, University of Milano-Bicocca Italy, Italy